Skip to main content

Arcus Biosciences, Inc.

RCUS
Exchange
NYSE
Industry
Pharmaceutical Preparations
SEC CIK
0001724521

In the last 90 days, Arcus Biosciences, Inc. insiders filed 0 open-market purchases and 1 sale; 243 institutions reported holding it in 13F filings for Q3 2026, worth $3.23B in total; no superinvestor holds it.

Key figures

Market capClose on Nov 20, 2026
$2.25B
Insider buysOpen market, last 90 days
0
Insider sellsLast 90 days, $84.8K in total
1
13F holdersQ3 2026, +18 vs. previous quarter
243
13F valueReported value at the end of Q3 2026
$3.23B
Superinvestors holdingAt the end of Q3 2026
0

Price chart

From SEC filings, in USD.

Revenue, FY2025
$247.0M
−4.3% year over year
Net income, FY2025
-$353.0M
No comparable prior period
Free cash flow, FY2025
-$484.0M
No comparable prior period
Revenue, Q3 FY2026
$9.00M
−65.4% year over year

Revenue flow, FY2025

Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue.

Net loss for FY2025: $353.0M (142.9% of revenue).

Short interest

See short data

From FINRA, settlement date Oct 30, 2026.

Short interest
13.2M
Shares sold short
Change
+819.3K
+6.6% vs. previous
Days to cover
3.56
At average daily volume

Superinvestors holding RCUS, Q3 2026

Go to the superinvestors tab

No superinvestor reported holding RCUS at the end of Q3 2026.

Latest insider trades

See all insider trades

Open-market purchases and sales by Arcus Biosciences, Inc. insiders from Form 4, newest first.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Aug 24, 2026 (view filing)5:52 PM ETAug 213 daysAzoy AlexanderChief Accounting OfficerSSale−2.83K$30.00−$84.8K−6.7%39.6K after10b5-1
Jul 13, 2026 (view filing)5:36 PM ETJul 9-104 daysJaen Juan C.PresidentSSale−68.6K$29.63−$2.03M−7.7%822.2K after3 lots10b5-1
Jun 24, 2026 (view filing)Jun 22-242 daysJaen Juan C.PresidentSSale−31.4K$27.92−$877.5K−3.4%890.8K after4 lots10b5-1
Jun 1, 2026 (view filing)Jun 1Same dayAzoy AlexanderChief Accounting OfficerSSale−2.56K$25.77−$66.0K−6.1%39.6K after10b5-1
May 12, 2026 (view filing)May 111 dayGoeltz II Robert C.Chief Financial OfficerSSale−7.76K$25.63−$199.0K−8.4%84.2K after10b5-1
Jan 7, 2026 (view filing)Jan 52 daysJaen Juan C.PresidentSSale−31.8K$21.41−$681.3K−3.3%922.2K after3 lots10b5-1
Jan 2, 2026 (view filing)Dec 31, 20252 daysGoeltz II Robert C.Chief Financial OfficerSSale−6.55K$23.38−$153.2K−8.8%67.9K after10b5-1
Dec 18, 2025 (view filing)Dec 16-172 daysMarkus RichardChief Medical OfficerSSale−9.55K$22.01−$210.1K−12.7%65.6K after2 lots10b5-1
Dec 18, 2025 (view filing)Dec 16-172 daysTang Carolyn C.General CounselSSale−14.5K$22.01−$318.5K−10.4%124.7K after2 lots10b5-1
Dec 18, 2025 (view filing)Dec 16-182 daysAzoy AlexanderChief Accounting OfficerSSale−8.83K$22.13−$195.4K−32.3%18.5K after3 lots10b5-1

Top 10 13F holders, Q3 2026

See all 243 holders

The largest institutional positions in Arcus Biosciences, Inc. at the end of Q3 2026; share changes are against Q2 2026.

Institutions holding RCUS in Q3 2026
InstitutionSharesValue% of portfolioChange in sharesAction
Gilead Sciences, Inc.31,424,760$811.7M55.45%00.0%Unchanged
BlackRock, Inc.16,824,688$434.6M0.01%+408,439+2.5%Added
Wellington Management Group LLP6,169,222$159.4M0.03%+273,774+4.6%Added
State Street Corp5,570,292$143.9M0.00%−459,192−7.6%Reduced
Vanguard Portfolio Management LLC4,440,422$114.7M0.01%−35,106−0.8%Reduced
FMR LLC4,436,585$114.6M0.00%+386,828+9.6%Added
Vanguard Capital Management LLC3,931,334$101.5M0.00%+42,988+1.1%Added
Citadel Advisors LLC2,959,746$76.5M0.04%−175,311−5.6%Reduced
Woodline Partners LP2,854,798$73.7M0.22%−153,000−5.1%Reduced
Janus Henderson Group PLC2,538,648$65.6M0.03%+2,538,648New

Holders of 5% or more of RCUS

See all 2 holders and filings

Holders whose latest Schedule 13D or 13G filing reports 5% or more of Arcus Biosciences, Inc..

Largest holders of RCUS from 13D and 13G filings
HolderLatest formStakeChangeFirst filedLatest filingFiling
Gilead Sciences, Inc.13D/A24.70%31.4M shares−0.90 ppfrom 25.60%Feb 2, 20218 filingsAug 7, 2026SEC
BlackRock, Inc.13G/A10.40%12.7M shares+1.00 ppfrom 9.40%Oct 23, 20244 filingsJan 8, 2026SEC